Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company’s lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.

15 Dec 2009

African-American women in South Carolina more likely to have cervical cancer than white women

African-American women in South Carolina are 37 percent more likely to have cervical cancer than white women and have a death rate that is about 61 percent higher, according to a study by researchers at the University of South Carolina's Arnold School of Public Health.

11 Dec 2009

California's EWC program: Cuts alarm breast cancer survivors and advocates

Breast cancer survivors and advocates from all seven California Affiliates of Susan G. Komen for the Cure® signaled their alarm today at the recently announced cuts to California's Every Woman Counts program, which would effectively shut the doors to breast cancer screening services for 1.2 million low-income and uninsured women for the first six months of 2010.

11 Dec 2009

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

Enzo Biochem, Inc. announced today that its Enzo Clinical Lab division has entered into an exclusive marketing partnership covering the States of New York and New Jersey with privately-owned Ikonisys, Inc., of New Haven, CT, relating to Ikonisys’ proprietary oncoFISH® cervical test, a laboratory developed test for cervical cancer prevention.

10 Dec 2009

Roche launches new automated clinical laboratory system for HPV and CT/NG tests

Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.

10 Dec 2009

BD Diagnostics receives FDA clearance on Amplified DNA Assays

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.

From BD (Becton, Dickinson and Company) 8 Dec 2009

New data reveals insurance-based discrimination is more common among lower income women

According to an analysis of statewide data taken from 1998-2001, women in Oregon who made less than $50,000 a year were more than three times likely to report they were discriminated against by health providers because of their insurance status during pregnancy and delivery

5 Dec 2009

Scientists report cervarix vaccine offers protection against cervical cancer

The Cervarix vaccine provides protection against two types of human papillomavirus (HPV) for more than six years, US scientists have reported.

5 Dec 2009

New Center for Digestive Care to care for all aspects of digestive disease

The Center for Digestive Care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has been established with a mission to provide high-quality patient care, research and education for all aspects of digestive disease.

4 Dec 2009

Scientists discover mechanism by which E6 oncoprotein of high-risk HPV16 promotes carcinogenesis

In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to degenerate. It is known today that the main culprits are viral proteins E6 and E7. Both proteins switch off different cellular control functions, thus promoting cell growth.

4 Dec 2009

Senate approves women's screening amendment in first health bill vote

The Associated Press: The Senate voted 61-39 Thursday "to safeguard coverage of mammograms and preventive screening tests for women under any health care overhaul legislation." The revision, which was advanced by Sen. Barbara Mikulski, D-Md., Sen. Olympia Snowe, R-Maine, "would allow the Health and Human Services secretary to require insurers to cover preventive health screenings free of charge" (Alonso-Zaldivar, 12/3).

3 Dec 2009

Integrated eating disorders center to be launched shortly

NewYork-Presbyterian Hospital, Weill Cornell Medical College and Columbia University College of Physicians and Surgeons, in affiliation with the New York State Psychiatric Institute, announced the creation of an integrated eating disorders center. Opening today is a key clinical component of this new center -- The Outlook at NewYork-Presbyterian Hospital/Westchester Division in White Plains.

2 Dec 2009

MAbs for early detection of cancer

Two sets of recommendations issued earlier this month have revised longstanding guidelines concerning the age at which women should first be tested for breast and cervical cancer and how frequently.

1 Dec 2009

Tripep completes phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology.

30 Nov 2009

Royal Philips Electronics demonstrates its portfolio of dose radiation managing products

Royal Philips Electronics today announced its response to an industry need by showing its portfolio of products designed to manage dose radiation at this year's 95th annual meeting of the Radiological Society of North America (RSNA) in Chicago.

From Philips Healthcare 30 Nov 2009

Study on deaths from cancer in Europe shows steady decline in mortality

New figures on deaths from cancer in Europe show a steady decline in mortality between the periods 1990-1994 and 2000-2004. Deaths from all cancers in the European Union (EU) between these two periods fell by nine percent in men and eight percent in women, with a large drop among the middle-aged population.

29 Nov 2009

Researchers uncover atomic-level action of ring-shaped protein motors

The atomic-level action of a remarkable class of ring-shaped protein motors has been uncovered by researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab) using a state-of-the-art protein crystallography beamline at the Advanced Light Source (ALS).

25 Nov 2009

Several new vaccines require booster shots to remain effective during a lifetime: Study

Preventing disease is the goal of every health care provider and fortunately every year, new vaccines are being added to assist in disease prevention. But do all vaccines boost immunity for the same period of time? And, if not, when are additional 'booster shots' needed to keep immunity strong?

24 Nov 2009

DSS sets evidence-based guidelines and definitions to treat type 2 diabetes

A first-of-its-kind consensus statement on diabetes surgery is published online today in the Annals of Surgery. The report illustrates the findings of the first international consensus conference -- Diabetes Surgery Summit (DSS) -- where an international group of more than 50 scientific and medical experts agreed on a set of evidence-based guidelines and definitions that are meant to guide the use and study of gastrointestinal surgery to treat type 2 diabetes. The document is considered to be the foundation of diabetes surgery as a medical discipline of its own.

24 Nov 2009

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. By exploiting this mechanism, researchers have been able to powerfully suppress tumor formation in lab testing and in animal models.

22 Nov 2009